Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MG1111 in Healthy Adults
NCT02367638Phase 1Completed
- Sponsor
- GC Biopharma
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 1, randomised, single-blind trial of varicella vaccine live in varicella (VZV) (2 arms), sponsored by GC Biopharma. Primary endpoints: Solicited and Unsolicited Adverse Events at 7 days and Unsolicited Adverse Events at 42 days. Started Mar 2015; status: completed.
02
Drugs
varicella vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT02367638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367638.